Results 101 to 110 of about 17,391 (234)
Clinical Pharmacology &Therapeutics, Volume 117, Issue 4, Page 910-919, April 2025.Recent discussions about the utilization of real‐world data (RWD) and real‐world evidence (RWE) have been more focused on drug development for regulatory approval rather than during the post‐marketing stage. In Japan, RWD/RWE have been practically utilized as an external control for drug approval.
Junichi Asano +5 more
wiley +1 more source
Adjusting Dlco for Hemoglobin: Using the Correct Equation
, 2022 Lydia Bachman
openalex +1 more source
Biomarkers of lung congestion and injury in acute heart failure
ESC Heart Failure, Volume 12, Issue 2, Page 781-789, April 2025.Abstract Acute heart failure (AHF) classification and management are primarily based on lung congestion and/or hypoperfusion. The quantification of the vascular and tissue lung damage is not standard practice though biomarkers of lung injury may play a relevant role in this context.
Marco Guazzi +9 more
wiley +1 more source
Clinicopathological Features of Mixed Connective Tissue Disease‐Related Myositis: A Case Series
Muscle &Nerve, Volume 71, Issue 4, Page 583-592, April 2025.ABSTRACT Introduction Mixed connective tissue disease (MCTD) patients often have myositis, however, myopathological and clinical data for MCTD are limited. Recent reports have shown that the pathology of MCTD myositis resembles that of immune‐mediated necrotizing myopathy (IMNM), whereas earlier reports described perifascicular atrophy or inflammatory ...
Naohiro Sakamoto +4 more
wiley +1 more source
Scientific ReportsLimited information is available regarding the association between preoperative lung function and postoperative pulmonary complications (PPCs) in patients with esophageal cancer who undergo esophagectomy. This is a retrospective cohort study.
Taeyun Kim +17 more
doaj +1 more source
Pediatric Pulmonology 2024 Year in Review: Rare and Diffuse Lung Disease
Pediatric Pulmonology, Volume 60, Issue 4, April 2025.ABSTRACT The field of pediatric rare and diffuse lung diseases continues to advance, with ongoing research deepening our understanding of the diagnosis and treatment of conditions such as children's interstitial and diffuse lung disease (chILD), non‐cystic fibrosis (CF) bronchiectasis, and pulmonary complications of childhood cancer.
Pi Chun Cheng +3 more
wiley +1 more source
Pulmonary Circulation, Volume 15, Issue 2, April 2025.ABSTRACT Pulmonary arterial hypertension (PAH) is a disease that can eventually progress to right ventricular failure. Heart rate variability (HRV), including standard deviation of R‐to‐R intervals (SDNN), has been associated with increased mortality across different populations.
Arun Jose +4 more
wiley +1 more source
A Prospective Analysis of Vasoreactivity and Mortality in WHO Group 3 Pulmonary Hypertension
Pulmonary Circulation, Volume 15, Issue 2, April 2025.ABSTRACT Prognostic markers of Group 3 pulmonary hypertension (PH) remain largely unknown. In this study, we evaluate clinical data to provide a comprehensive profile of patients with Group 3 PH and evaluate the potential use of vasoreactivity testing as a prognostic tool within this population.
Daniel J. Strick +6 more
wiley +1 more source
Scientific ReportsThe progression of idiopathic pulmonary fibrosis (IPF) is assessed through serial monitoring of forced vital capacity (FVC). Currently, data regarding the clinical significance of longitudinal changes in diffusing capacity for carbon monoxide (DLCO) is ...
Hyeonsu Lee +5 more
doaj +1 more source
Correlation between Measurement of Lung Diffusion Capacity Using Single Breath Methods (DLCO-SB) and COPD Group in Persahabatan Hospital Jakarta [PDF]
, 2021 Efriadi Ismail +2 more
openalex +1 more source